Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SumayaVac-1 in Healthy Malaria-Exposed Adults
NCT05644067Phase 1Completed
- Sponsor
- Swiss Tropical and Public Health Institute
- Start
- Aug 2023
- Primary completion
- Apr 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SUM-101 in malaria (2 arms), sponsored by Swiss Tropical and Public Health Institute. Primary endpoints: Local and systemic adverse events (AEs), Local and systemic unsolicited reactogenicity and 4 more. Started Aug 2023; status: completed.
02
Drugs
SUM-101
03
Conditions
malaria
Beyond the preview
Go deeper on NCT05644067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05644067.